Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Seaport Therapeutics ended the second quarter with $427.3 million in cash and equivalents, providing a runway into 2029 following its May IPO that raised $260 million in gross proceeds. Clinically, the company reported positive Phase 1 data for GlyphAgo, showing a 6.8-fold increase in bioavailability, and plans to initiate Phase 2 trials in the second half of 2026.
Key figures
- Revenue
- 0
- Revenue Yoy
- 0
- Net loss
- 62600000
- Ga expenses
- 41189000
- Rd expenses
- 24619000
- Ipo proceeds
- 260000000
- Cash position
- 427260000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.